Skadden Steers Endo’s $1.6B Paladin Labs Buy

Law360, New York (November 5, 2013, 1:40 PM EST) -- Endo Health Solutions Inc. inked a $1.6 billion acquisition of Canada-based competitor Paladin Labs Inc., bolstering the pharmaceutical giant’s platform for international growth, according to an announcement Tuesday.

About 98 percent of the transaction will be funded with shares of stock, valuing Paladin Labs shares at CA$77 (US$73.97) each, a 20 percent premium on its current share price of CA$63.91, according to a statement.

The acquisition of Paladin Labs serves to further transform the integrated health solutions company into a global leader in the health care...
To view the full article, register now.